Evgen Pharma PLC SFX-01 featured in Nature Reviews Drug Discovery
23 Gennaio 2019 - 8:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
23 January 2019
For immediate release 23 January 2019
RNS REACH
Evgen Pharma plc
("Evgen" or "the Company")
Lead product SFX-01 featured in Nature Reviews Drug
Discovery
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that both Evgen and its lead product, SFX-01,
are considered in a recently published paper in Nature Reviews Drug
Discovery entitled 'Therapeutic targeting of the Nrf2 and KEAP1
partnership in chronic diseases'.
The paper, in which Evgen CEO Stephen Franklin is a co-author,
is a comprehensive and authoritative review of the importance of
the Nrf2 pathway in the maintenance of redox, metabolic and protein
homeostasis, as well as the regulation of inflammation. Evidence is
presented showing that Nrf2 activation provides cytoprotection
against numerous pathologies including chronic diseases of the lung
and liver; autoimmune, neurodegenerative and metabolic disorders;
and cancer initiation.
The paper also reviews the status of Nrf2 modulators in clinical
development of which SFX-01 is one of the more advanced.
The abstract of the paper can be viewed at
https://www.ncbi.nlm.nih.gov/pubmed/30610225
The full paper will be available to those with an academic
institute affiliation or can be purchased or rented at
https://www.nature.com/articles/s41573-018-0008-x
Dr Stephen Franklin, CEO of Evgen, commented:
"I am delighted that both the significance of the Nrf2 pathway
in many chronic diseases, and equally the promise of Nrf2
activators including SFX-01, in treating these diseases has been
emphasised in such a prestigious journal thus further endorsing
Evgen's approach and pipeline."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
finnCap
Geoff Nash, Teddy Whiley (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
www.finncap.com +44 (0) 20 7220 0500
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Buchanan
Mark Court, Sophie Wills, Tilly
Abraham
evgen@buchanan.uk.com +44 (0) 20 7466 5000
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead
programmes are in breast cancer and subarachnoid haemorrhage, a
type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALLFSRLFIFFIA
(END) Dow Jones Newswires
January 23, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024